Search results for "Glycemic Control"

showing 10 items of 18 documents

Honey and obesity-related dysfunctions: a summary on health benefits

2020

Honey is a natural product, containing flavonoids and phenolic acids, appreciated for its therapeutic abilities since ancient times. Although the bioactive potential is linked to the composition, that is variable depending on mainly the botanical origin, honey has antioxidant and anti-inflammatory properties. Therefore, honey, administered alone or in combination with conventional therapy, might result useful in the management of chronic diseases that are commonly associated with oxidative stress and inflammation state. Obesity is a metabolic disorder characterized by visceral adiposity. The adipose tissue becomes hypertrophic and undergoes hyperplasia, resulting in a hypoxic environment, o…

0301 basic medicineHealth StatusEndocrinology Diabetes and MetabolismClinical BiochemistryAnti-Inflammatory AgentsAdipose tissueGlycemic Controlmedicine.disease_causeBioinformaticsBiochemistryAntioxidants03 medical and health sciences0302 clinical medicineHydroxybenzoatesAnimalsHumansMedicineObesityNeurodegenerationMolecular BiologyGlycemicFlavonoidsInflammationMetabolic SyndromeHyperplasiaNutrition and Dieteticsmedicine.diagnostic_testbusiness.industryfungiMetabolic disorderNeurodegenerationPolyphenolsfood and beveragesNeurodegenerative DiseasesHoneymedicine.diseaseObesityOxidative Stress030104 developmental biologyDiabetes Mellitus Type 2HypertensionOxidative streInsulin ResistanceMetabolic syndromebusinessLipid profile030217 neurology & neurosurgeryOxidative stressThe Journal of Nutritional Biochemistry
researchProduct

Mitochondrial DNA Haplogroup JT is Related to Impaired Glycaemic Control and Renal Function in Type 2 Diabetic Patients

2018

The association between mitochondrial DNA (mtDNA) haplogroup and risk of type 2 diabetes (T2D) is undetermined and controversial. This study aims to evaluate the impact of the main mtDNA haplogroups on glycaemic control and renal function in a Spanish population of 303 T2D patients and 153 healthy controls. Anthropometrical and metabolic parameters were assessed and mtDNA haplogroup was determined in each individual. Distribution of the different haplogroups was similar in diabetic and healthy populations and, as expected, T2D patients showed poorer glycaemic control and renal function than controls. T2D patients belonging to the JT haplogroup (polymorphism m.4216T&gt

0301 basic medicinemedicine.medical_specialtyendocrine system diseasesgenetic structurestype 2 diabetes mellituslcsh:MedicineRenal functionType 2 diabetesArticleHaplogroupNephropathyDiabetic nephropathy03 medical and health scienceschemistry.chemical_compoundInternal medicineMedicineCreatininebusiness.industrymtDNAlcsh:Rmitochondrial haplogroupType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseeye diseaseshumanities030104 developmental biologyEndocrinologychemistryglycemic controlnephropathybusinessHuman mitochondrial DNA haplogroup
researchProduct

Maternal Parenting Styles and Glycemic Control in Children with Type 1 Diabetes

2019

The purpose of this study is to examine differences in parenting styles between mothers of children with type 1 diabetes and mothers of healthy children and to explore relationships between parenting styles and glycemic control of children with diabetes. Mothers of 63 children with diabetes and mothers of 83 children without diabetes reported their parenting styles using the Blocks&rsquo

AdultBlood GlucoseMaleglykeeminen indeksitype 1 diabetesHealth Toxicology and MutagenesisControl (management)Mothers030209 endocrinology & metabolismArticle03 medical and health sciencesChild Rearing0302 clinical medicinechildrenPsychological controlDiabetes mellitusParenting stylesmedicineHumans030212 general & internal medicineChildta515GlycemicType 1 diabetesdiabetesParentingChild rearingbusiness.industrynuoruustyypin diabetesPublic Health Environmental and Occupational Healthta3142medicine.diseaseäiditparenting stylevanhemmatDiabetes Mellitus Type 1kontrolliglycemic controlFemalebusinessClinical psychologyInternational Journal of Environmental Research and Public Health
researchProduct

Myoinositol supplementation in the treatment of gestational diabetes mellitus: effects on glycaemic control and maternal-foetal outcomes.

2022

Abstract Background Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset during pregnancy. It is characterized by high risk of adverse outcomes for the mother and the foetus, if not adequately controlled. The aim of the study was to evaluate the effects of 4000 mg of myoinositol supplementation in women with GDM on maternal-foetal outcomes, compared to controls. Methods A cohort of 330 women with GDM, 150 supplemented with myoinositol and 180 controls were enrolled. Clinical and metabolic parameters and the prevalence of maternal and foetal complications were assessed. Results The same number of women in the two groups started insulin as additional therapy. Women…

Blood GlucoseInfant NewbornObstetrics and GynecologyGlycemic ControlDiabetes GestationalBirth weightInsulin requirementPregnancyDietary SupplementsHumansInsulinPremature BirthFemaleNUtrition.Glucose intoleranceHypoglycaemiaInositolBMC pregnancy and childbirth
researchProduct

A Worldwide Perspective on COVID-19 and Diabetes Management in 22,820 Children from the SWEET Project: Diabetic Ketoacidosis Rates Increase and Glyce…

2021

Aims: To investigate the short-term effects of the first wave of COVID-19 on clinical parameters in children with type 1 diabetes (T1D) from 82 worldwide centers participating in the Better Control in Pediatric and Adolescent DiabeteS: Working to CrEate CEnTers of Reference (SWEET) registry. Materials and Methods: Aggregated data per person with T1D £21 years of age were compared between May/June 2020 (first wave), August/September 2020 (after wave), and the same periods in 2019. Hierarchic linear and logistic regression models were applied. Models were adjusted for gender, age-, and diabetes duration-groups. To distinguish the added burden of the COVID-19 pandemic, the centers were divided…

Blood GlucoseMale2019-20 coronavirus outbreakPediatricsmedicine.medical_specialtyHbA1cAdolescentCoronavirus disease 2019 (COVID-19)Diabetic ketoacidosisEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030209 endocrinology & metabolismGlycemic Control03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes managementDiabetic ketoacidosisDiabetes mellitusHumansMedicine030212 general & internal medicineChildPandemicsChildrenGlycemicGlycated HemoglobinType 1 diabetesbusiness.industryCGMBlood Glucose Self-MonitoringCOVID-19CSIIBMI.medicine.diseaseMedical Laboratory TechnologyDiabetes Mellitus Type 1Type 1 diabetesFemalebusinessDiabetes Technology & Therapeutics
researchProduct

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1…

2012

OBJECTIVE We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change bet…

Blood GlucoseMaleEXENATIDEendocrine system diseasesdiabetes liraglutide metfortmin hypoglycemiaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesTHERAPYGastroenterologyMELLITUSInsulin DetemirGlucagon-Like Peptide 1GLYCEMIC CONTROLOriginal ResearchInsulin detemirAged 80 and overClinical Care/Education/Nutrition/Psychosocial ResearchTREATED PATIENTSMiddle AgedMetforminMetforminNPH INSULINInsulin Long-ActingFemaleLife Sciences & Biomedicinehormones hormone substitutes and hormone antagonistsmedicine.drugAdultmedicine.medical_specialtyPARALLEL-GROUPAdolescentmedicine.drug_classHypoglycemiaEndocrinology & MetabolismDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsCOMBINATIONAgedGlycated HemoglobinAdvanced and Specialized NursingScience & TechnologyLiraglutidebusiness.industryInsulin26-WEEKnutritional and metabolic diseasesLiraglutideEFFICACYmedicine.diseaseSulfonylureaEndocrinologyDiabetes Mellitus Type 2business
researchProduct

Timing of Exercise Affects Glycemic Control in Type 2 Diabetes Patients Treated with Metformin

2018

Objective. The purpose of the study was to examine the acute effects of the timing of exercise on the glycemic control during and after exercise in T2D. Methods. This study included 26 T2D patients (14 women and 12 men) who were treated with metformin. All patients were tested on four occasions: metformin administration alone (Metf), high-intensity interval training (HIIT) performed at 30 minutes (EX30), 60 minutes (EX60), and 90 minutes (EX90) postbreakfast, respectively. Glucose, insulin, and superoxide dismutase (SOD) activity were examined. Results. Glucose decreased significantly after the exercise in EX30, EX60, and EX90. Compared with Metf, the decline in glucose immediately after th…

Blood GlucoseMaleTime Factorsendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentmetformiiniajoitus (suunnittelu)Type 2 diabetes030204 cardiovascular system & hematologyHigh-Intensity Interval TrainingGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologyInterval training0302 clinical medicineEndocrinologyInsulinta315type 2 diabetes patientskuntoliikuntata3141Middle Agedtiming of exerciseMetforminFemaleHigh-intensity interval trainingmedicine.drugAdultmedicine.medical_specialtyArticle Subject030209 endocrinology & metabolism03 medical and health sciencesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsExercise physiologyExerciseGlycemiclcsh:RC648-665business.industrySuperoxide DismutaseInsulinmedicine.diseaseDiabetes Mellitus Type 2verensokeriClinical Studyglycemic controlbusinessmetforminaikuistyypin diabetesJournal of Diabetes Research
researchProduct

Associations of resting and peak fat oxidation with sex hormone profile and blood glucose control in middle-aged women.

2022

Background and Aims Menopause may reduce fat oxidation. We investigated whether sex hormone profile explains resting fat oxidation (RFO) or peak fat oxidation (PFO) during incremental cycling in middle-aged women. Secondarily, we studied associations of RFO and PFO with glucose regulation. Method and Results We measured RFO and PFO of 42 women (age 52–58 years) with indirect calorimetry. Seven participants were pre- or perimenopausal, 26 were postmenopausal, and nine were postmenopausal hormone therapy users. Serum estradiol (E2), follicle-stimulating hormone, progesterone, and testosterone levels were quantified with immunoassays. Insulin sensitivity (Matsuda index) and glucose tolerance (…

Blood GlucoseestradioliNutrition and Dieteticsvaihdevuodetglucose toleranceEndocrinology Diabetes and MetabolismhapettuminenmenopauseMedicine (miscellaneous)fat oxidationGlycemic ControlMiddle Agedinsuliiniresistenssirasva-aineenvaihduntahormonaaliset tekijätGlucoseglukoosi-intoleranssiestradiolBody Compositioninsulin sensitivityHumansFemaleInsulin ResistanceCardiology and Cardiovascular MedicineGonadal Steroid HormonesNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Hydroxychloroquine, COVID ‐19 and diabetes. Why it is a different story

2020

Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.

Blood Glucosemedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINE030209 endocrinology & metabolismGlycemic Control030204 cardiovascular system & hematologySeverity of Illness IndexDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyCommentariesInternal medicineDiabetes mellitusSeverity of illnessDiabetes MellitusInternal MedicinemedicineHyperglycaemiaHumansHypoglycemic AgentsBlood Glucose COVID-19 Diabetes Complications Diabetes Mellitus Glycemic Control Humans Hydroxychloroquine Hypoglycemic Agents SARS-CoV-2 Severity of Illness Index Signal TransductionSARS-CoV-2business.industryDiabetesCOVID-19Hydroxychloroquinemedicine.diseaseCOVID-19 Drug TreatmentACE2 Cardiovascular disease COVID‐19CommentarybusinessHydroxychloroquineSignal Transductionmedicine.drugDiabetes/Metabolism Research and Reviews
researchProduct

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain.

2020

ObjectiveObservations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings.Research design and methodsDeidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose parameters were calculated for each group: estimated HbA1c, time below range (<70 and ≤54 mg/dL), within range (70–180 mg/dL), and above range (>180 mg/dL). Glycemic variability (GV) metrics were desc…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypoglycemialaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineDiabetes mellitusmedicineHumans030212 general & internal medicine1506GlycemicBlood glucose monitoringmedicine.diagnostic_testbusiness.industryBlood Glucose Self-MonitoringEmerging Technologies Pharmacology and Therapeuticsmedicine.diseaseDiabetes Mellitus Type 1GlucosehypoglycemiaSpainCardiologyglycemic controlblood glucose monitoringbusinessReal world dataBMJ open diabetes researchcare
researchProduct